Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Onconova Therapeutic (NQ: ONTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Onconova Therapeutic < Previous 1 2 Next > Traws Pharma Announces New Employee Inducement Grants April 02, 2024 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company April 02, 2024 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024 March 08, 2024 Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma December 12, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s December 08, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference November 28, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results November 14, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023 November 07, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL November 02, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Expands Leadership Team with Two Key Appointments October 24, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Promising Preclinical Narazaciclib Data Presented at MCL Meeting October 19, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Encouraging Rigosertib Data Presented at EADV as Late Breaker October 12, 2023 Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress September 28, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference September 06, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results August 10, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023 August 03, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma June 14, 2023 Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting June 05, 2023 Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade May 25, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 15, 2023 Conference call and live webcast at 4:30 p.m. ET today From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer May 12, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer May 11, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium May 08, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023 May 04, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting April 19, 2023 Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6 inhibitors From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder April 06, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib March 23, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update March 16, 2023 Conference call and live webcast at 4:30 p.m. ET today From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting March 15, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 March 09, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023 From Onconova Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.